BD Unveils Innovative Bioabsorbable Mesh for Umbilical Hernia Treatment

BD Launches Revolutionary Phasix™ ST Umbilical Hernia Patch

In a significant advancement in the field of surgical care, BD (Becton, Dickinson and Company) has announced the launch of the Phasix™ ST Umbilical Hernia Patch, marked as the first fully absorbable hernia patch tailored for umbilical repair. On April 23, 2025, BD received 510(k) clearance from the U.S. FDA, allowing this innovative product to hit the market. This new patch is designed to enhance the efficacy and safety of hernia repairs, responding to the growing demand for non-permanent options.

Dr. Robert Harrell, a prominent general surgeon based in Texas, expressed his excitement about the product's arrival, saying, "I've been waiting and hoping for this product to come to market for many years, and I'm thrilled that it's finally here for us to use." He points to a fusion of technologies, noting the combination of features from the previously established Ventralex™ ST Hernia Patch integrated with the bioabsorbable nature of the Phasix™ Mesh.

The Phasix™ ST Umbilical Hernia Patch is composed of Poly-4-hydroxybutyrate (P4HB), a biologically sourced material, augmented by a hydrogel barrier created using Sepra® Technology. This ensures optimal absorbability and a responsive healing process post-surgery. The patch leverages traditional surgical techniques similar to those employed with conventional permanent mesh options. Its design facilitates ease of placement and stability through its unique pocket and strap design.

This product serves as a necessary alternative in a healthcare landscape that increasingly favors non-permanent solutions. Recent surveys reveal that approximately 60% of patients prefer biodegradable materials for hernia repairs, and there is strong enthusiasm among surgeons, with over 70% willing to consider patient preferences in their decision-making.

As Ron Silverman, BD's chief medical officer, remarked, "BD is redefining tissue repair through advanced biomaterials and expanding treatment options to meet individual patient needs through proven, reliable alternatives to permanent mesh." This launch signifies another pivotal milestone in hernia repair innovation, reinforcing BD's position at the forefront of advancements in biomaterial science and their application in clinical procedures.

The Phasix™ ST Umbilical Hernia Patch is available in three distinct sizes, providing flexibility to address a variety of umbilical soft tissue defects while accommodating surgical preferences for appropriate overlap. This addition expands BD's portfolio of absorbable products, which has already seen great success with over 385,000 implants performed globally to date.

BD’s commitment to healthcare innovations aims not only to enhance clinical outcomes but also to improve the overall experience for healthcare providers and their patients. The introduction of the Phasix™ ST Umbilical Hernia Patch thus represents a forward-thinking approach to surgical interventions. The emphasis on biomaterials marks a transformative change within the sector, showcasing BD's dedication to supporting healthcare professionals by providing safe and effective tools for treatment.

As BD continues to evolve, their role as a leader in medical technology becomes increasingly evident, advocating for advancements that align with modern-day healthcare practices. This new product reflects an ongoing journey driven by research, innovation, and an unwavering commitment to improving patient care.